Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson’s disease
Danna Jennings, Sarah Huntwork‐Rodriguez, Anastasia G. Henry, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 648
Closed Access | Times Cited: 162

Showing 1-25 of 162 citing articles:

Discovery of XL01126: A Potent, Fast, Cooperative, Selective, Orally Bioavailable, and Blood–Brain Barrier Penetrant PROTAC Degrader of Leucine-Rich Repeat Kinase 2
Xingui Liu, Alexia F. Kalogeropulou, Sofia Domingos, et al.
Journal of the American Chemical Society (2022) Vol. 144, Iss. 37, pp. 16930-16952
Open Access | Times Cited: 110
Medical, surgical, and physical treatments for Parkinson's disease
Thomas Foltynie, Verónica Bruno, Susan H. Fox, et al.
The Lancet (2024) Vol. 403, Iss. 10423, pp. 305-324
Open Access | Times Cited: 73
Perspective on the current state of the LRRK2 field
Jean‐Marc Taymans, Matt Fell, Tim Greenamyre, et al.
npj Parkinson s Disease (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 70
LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson's Disease
Danna Jennings, Sarah Huntwork‐Rodriguez, Maurits F. J. M. Vissers, et al.
Movement Disorders (2023) Vol. 38, Iss. 3, pp. 386-398
Open Access | Times Cited: 45
Leucine-Rich Repeat Kinases
Dario R. Alessi, Suzanne R. Pfeffer
Annual Review of Biochemistry (2024) Vol. 93, Iss. 1, pp. 261-287
Closed Access | Times Cited: 17
Current Treatments and New, Tentative Therapies for Parkinson’s Disease
Teresa Pardo-Moreno, Victoria García‐Morales, Nora Suleiman‐Martos, et al.
Pharmaceutics (2023) Vol. 15, Iss. 3, pp. 770-770
Open Access | Times Cited: 39
Rab29-dependent asymmetrical activation of leucine-rich repeat kinase 2
Hanwen Zhu, Francesca Tonelli, Martin Turk, et al.
Science (2023) Vol. 382, Iss. 6677, pp. 1404-1411
Open Access | Times Cited: 39
Genome-wide screen reveals Rab12 GTPase as a critical activator of Parkinson’s disease-linked LRRK2 kinase
Herschel S. Dhekne, Francesca Tonelli, Wondwossen M Yeshaw, et al.
eLife (2023) Vol. 12
Open Access | Times Cited: 36
Autophagy in Parkinson’s Disease
Lior Nechushtai, Dan Frenkel, Ronit Pinkas‐Kramarski
Biomolecules (2023) Vol. 13, Iss. 10, pp. 1435-1435
Open Access | Times Cited: 34
LRRK2 suppresses lysosome degradative activity in macrophages and microglia through MiT-TFE transcription factor inhibition
Narayana Yadavalli, Shawn M. Ferguson
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 31
Open Access | Times Cited: 33
LRRK2 and Parkinson's disease: from genetics to targeted therapy
Yuri L. Sosero, Ziv Gan‐Or
Annals of Clinical and Translational Neurology (2023) Vol. 10, Iss. 6, pp. 850-864
Open Access | Times Cited: 31
Translational molecular imaging and drug development in Parkinson’s disease
Ahmed Haider, Nehal H. Elghazawy, Alyaa Dawoud, et al.
Molecular Neurodegeneration (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 30
Small-molecule LRRK2 inhibitors for PD therapy: Current achievements and future perspectives
Jiarui Hu, Dan Zhang, Keyue Tian, et al.
European Journal of Medicinal Chemistry (2023) Vol. 256, pp. 115475-115475
Closed Access | Times Cited: 27
Overlapping Neuroimmune Mechanisms and Therapeutic Targets in Neurodegenerative Disorders
Fabiola De Marchi, Ivana Munitić, Lea Vidatic, et al.
Biomedicines (2023) Vol. 11, Iss. 10, pp. 2793-2793
Open Access | Times Cited: 26
Rare variants with large effects provide functional insights into the pathology of migraine subtypes, with and without aura
Gyða Björnsdóttir, Mona Ameri Chalmer, Lilja Stefánsdóttir, et al.
Nature Genetics (2023) Vol. 55, Iss. 11, pp. 1843-1853
Open Access | Times Cited: 23
Pharmacology of LRRK2 with type I and II kinase inhibitors revealed by cryo-EM
Hanwen Zhu, Patricia Hixson, Wen Ma, et al.
Cell Discovery (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 15
A potential patient stratification biomarker for Parkinson´s disease based on LRRK2 kinase-mediated centrosomal alterations in peripheral blood-derived cells
Yahaira Naaldijk, Belén Fernández, Rachel Fasiczka, et al.
npj Parkinson s Disease (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 11
Parkinson disease therapy: current strategies and future research priorities
Fabrizio Stocchi, Daniele Bravi, Aron Emmi, et al.
Nature Reviews Neurology (2024) Vol. 20, Iss. 12, pp. 695-707
Closed Access | Times Cited: 10
G2019S selective LRRK2 kinase inhibitor abrogates mitochondrial DNA damage
Nicholas Pena, Tara Richbourg, Claudia P. González-Hunt, et al.
npj Parkinson s Disease (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 9
Uncovering the genetic basis of Parkinson's disease globally: from discoveries to the clinic
Shen‐Yang Lim, Ai Huey Tan, Azlina Ahmad, et al.
The Lancet Neurology (2024)
Closed Access | Times Cited: 9
Chaperone-Mediated Autophagy in Neurodegenerative Diseases: Molecular Mechanisms and Pharmacological Opportunities
Yi-Ting Wang, Jiahong Lu
Cells (2022) Vol. 11, Iss. 14, pp. 2250-2250
Open Access | Times Cited: 33
Rab12 is a regulator of LRRK2 and its activation by damaged lysosomes
Xiang Wang, Vitaliy V. Bondar, Oliver B. Davis, et al.
eLife (2023) Vol. 12
Open Access | Times Cited: 22
Kinases control of regulated cell death revealing druggable targets for Parkinson’s disease
Heba M. Mansour, Ahmed F. Mohamed, Aiman S. El‐Khatib, et al.
Ageing Research Reviews (2023) Vol. 85, pp. 101841-101841
Closed Access | Times Cited: 21
Towards a multi-arm multi-stage platform trial of disease modifying approaches in Parkinson’s disease
Thomas Foltynie, Sonia Gandhi, Cristina Gonzalez‐Robles, et al.
Brain (2023) Vol. 146, Iss. 7, pp. 2717-2722
Open Access | Times Cited: 20
Inhibition of Parkinson’s disease–related LRRK2 by type I and type II kinase inhibitors: Activity and structures
Marta Sanz Murillo, Amalia Villagran Suarez, Verena Dederer, et al.
Science Advances (2023) Vol. 9, Iss. 48
Open Access | Times Cited: 20
Page 1 - Next Page

Scroll to top